← Leaderboards
Bruno Calabretta
Thomas Jefferson University
$9,620,602
Attributed
$13,674,873
Total exposure
9
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.7M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$22,566,691 · 10
By mechanism
R01$11,730,718 · 5
P01$9,700,389 · 3
T32$1,135,584 · 2
Top collaborators
- Alexander M Mazo8 shared
- Joseph M Salvino5 shared
- Andrew E Aplin3 shared
Most similar at Thomas Jefferson University
Same institution · by research overlap
- Thea Friedman$3,221,424
- Sara E Meyer$2,462,265
- Alexander M Mazo$10,970,170
- Robert Korngold$9,942,144
- Michael Lawler$94,446
Others in their field
Top investigators on “Leukemia”
- Richard K. Wilson · Washington University$209,620,938
- David Heimbrook · Leidos Biomedical Research, Inc.$168,419,678
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,967,203
- Peter C Adamson · National Childhood Cancer Foundation$143,910,899
- Ralph Parchment · Leidos Biomedical Research, Inc.$141,315,269
- Richard L Schilsky · University Of Chicago$129,102,207
Research focus
LeukemiaTranscription FactorCellsHematopoietic Stem CellsBiologicalGene ExpressionGenetic TranscriptionMolecularExhibitsGenesCancer BiologyProteinsCell CycleBaseStem CellsApoptosisMalignant NeoplasmsCancer TherapyGrowthHematologic NeoplasmsMouse ModelIn VitroIn VivoLaboratories
Grant awards (45)
Targeting CDK6 expression/activity in Ph+ and Ph1-like acute lymphoblastic leukemia (ALL)$631,337
R01 · FY2025 · CA · contact PI
A novel strategy for transcriptional reprogramming of lymphoid leukemia cells$540,022
R01 · FY2025 · CA · contact PI
Targeting CDK6 expression/activity in Ph+ and Ph1-like acute lymphoblastic leukemia (ALL)$599,770
R01 · FY2024 · CA · contact PI
A novel strategy for transcriptional reprogramming of lymphoid leukemia cells$514,253
R01 · FY2024 · CA · contact PI
Targeting CDK6 expression/activity in Ph+ and Ph1-like acute lymphoblastic leukemia (ALL)$618,711
R01 · FY2023 · CA · contact PI
A novel strategy for transcriptional reprogramming of lymphoid leukemia cells$529,222
R01 · FY2023 · CA · contact PI
Targeting CDK6 expression/activity in Ph+ and Ph1-like acute lymphoblastic leukemia (ALL)$618,711
R01 · FY2022 · CA · contact PI
A novel strategy for transcriptional reprogramming of lymphoid leukemia cells$540,022
R01 · FY2022 · CA · contact PI
Targeting CDK6 expression/activity in Ph+ and Ph1-like acute lymphoblastic leukemia (ALL)$645,339
R01 · FY2021 · CA · contact PI
Training Program in Cancer Biology$247,871
T32 · FY2021 · CA · contact PI
Training Program in Cancer Biology$269,223
T32 · FY2020 · CA · contact PI
The role of chromatin structure in differentiation of hematopoietic stem cells$526,059
R01 · FY2019 · HL · contact PI
Training Program in Cancer Biology$249,826
T32 · FY2019 · CA · contact PI
The role of chromatin structure in differentiation of hematopoietic stem cells$526,059
R01 · FY2018 · HL · contact PI
The role of chromatin structure in differentiation of hematopoietic stem cells$526,059
R01 · FY2017 · HL · contact PI
Targeting the C/EBPalpha-Gfi-pathway in CML stem cells$321,625
R01 · FY2017 · CA · contact PI
The role of chromatin structure in differentiation of hematopoietic stem cells$526,059
R01 · FY2016 · HL · contact PI
Targeting the C/EBPalpha-Gfi-pathway in CML stem cells$321,625
R01 · FY2016 · CA · contact PI
Targeting the C/EBPalpha-Gfi-pathway in CML stem cells$321,625
R01 · FY2015 · CA · contact PI
Targeting the C/EBPalpha-Gfi-pathway in CML stem cells$311,976
R01 · FY2014 · CA · contact PI
Targeting the C/EBPalpha-Gfi-pathway in CML stem cells$321,625
R01 · FY2013 · CA · contact PI
Transcription Factor Regulation by the BCR/ABL Oncogene$301,843
R01 · FY2012 · CA · contact PI
Transcription Factor Regulation by the BCR/ABL Oncogene$301,843
R01 · FY2011 · CA · contact PI
Transcription Factor Regulation by the BCR/ABL Oncogene$311,178
R01 · FY2010 · CA · contact PI
Transcription Factor Regulation by the BCR/ABL Oncogene$311,178
R01 · FY2009 · CA · contact PI
Cell Survival and Cancer$1,371,447
P01 · FY2007 · CA · contact PI
Cell Survival and Cancer$1,373,310
P01 · FY2006 · CA · contact PI
TRANSCRIPTION FACTOR REGULATION BY THE BCR/ABL ONCOGENE$307,005
R01 · FY2006 · CA · contact PI
Cell Survival and Cancer$1,367,486
P01 · FY2005 · CA
TRANSCRIPTION FACTOR REGULATION BY THE BCR/ABL ONCOGENE$314,393
R01 · FY2005 · CA
Cell Survival and Cancer$1,329,661
P01 · FY2004 · CA
TRANSCRIPTION FACTOR REGULATION BY THE BCR/ABL ONCOGENE$314,393
R01 · FY2004 · CA
Cell Survival and Cancer$1,290,933
P01 · FY2003 · CA
TRANSCRIPTION FACTOR REGULATION BY THE BCR/ABL ONCOGENE$314,393
R01 · FY2003 · CA
TRAINING IN HEMATOPOIETIC &VASCULAR CELL FUNCTIONS$103,504
T32 · FY2003 · HL
TRANSCRIPTION FACTOR REGULATION BY THE BCR/ABL ONCOGENE$314,393
R01 · FY2002 · CA
TRAINING IN HEMATOPOIETIC &VASCULAR CELL FUNCTIONS$86,586
T32 · FY2002 · HL
CELL SURVIVAL AND CANCER$1,093,996
P01 · FY2001 · CA
REGULATION OF CELL PROLIFERATION BY GENES OF THE MYB FAMILY$296,752
P01 · FY2001 · CA
TRAINING IN HEMATOPOIETIC &VASCULAR CELL FUNCTIONS$91,620
T32 · FY2001 · HL
Anti-Apoptotic Mechanisms in BCR/ABL Leukemogenesis$76,744
P01 · FY2001 · CA
CELL SURVIVAL AND CANCER$1,064,985
P01 · FY2000 · CA
REGULATION OF CELL PROLIFERATION BY GENES OF THE MYB FAMILY$224,570
P01 · FY2000 · CA
Anti-Apoptotic Mechanisms in BCR/ABL Leukemogenesis$210,505
P01 · FY2000 · CA
TRAINING IN HEMATOPOIETIC &VASCULAR CELL FUNCTIONS$86,954
T32 · FY2000 · HL